BackAkari Therapeutics Plc Overview

Akari Therapeutics Plc Accounts Payable

Track Akari Therapeutics Plc's accounts payable ($9.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$9.40M
19.01% YoYΔ $-2.21M vs prior year quarter

Peer trimmed avg / median

Loading

Akari Therapeutics Plc Accounts Payable History

Loading

Akari Therapeutics Plc vs. peers: Accounts Payable Comparison

Loading

Akari Therapeutics Plc Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Akari Therapeutics Plc (AKTX) FAQ

As of the most recent data (June 2026), AKTX shows a accounts payable of $9.4M. That compares with $12M in the prior-year period — down 19.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AKTX's accounts payable is now $9.4M (was $12M) — a 19.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Akari Therapeutics Plc is outperforming or lagging.

Tracking AKTX's accounts payable over time shows whether Akari Therapeutics Plc is scaling, shrinking, or reshaping that part of the business. The current reading is $9.4M That compares with $12M in the prior-year period — down 19.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Akari Therapeutics Plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $9.4M) with ownership activity and broader fundamentals.

Akari Therapeutics Plc's accounts payable is $9.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.